Technical Analysis for HTBX - Heat Biologics, Inc.

Grade Last Price % Change Price Change
grade F 0.74 0.68% 0.01
HTBX closed up 0.68 percent on Friday, May 24, 2019, on 2.12 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 28

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical HTBX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.68%
Volume Surge Other 0.68%
New 52 Week Low Weakness 0.68%
Wide Bands Range Expansion 0.68%
Below Lower BB Weakness 0.68%

Older signals for HTBX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Non Small Cell Lung Cancer Ovarian Cancer Vaccination Cancer Treatment HIV Platform Technology Vaccine Cancer Vaccine Treatment Of Non Small Cell Lung Cancer Biotechnology Companies Bladder Cancer Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
Is HTBX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.98
52 Week Low 0.7051
Average Volume 215,744
200-Day Moving Average 1.4477
50-Day Moving Average 1.0944
20-Day Moving Average 0.9324
10-Day Moving Average 0.8349
Average True Range 0.0716
ADX 46.61
+DI 7.733
-DI 33.8196
Chandelier Exit (Long, 3 ATRs ) 0.9152
Chandelier Exit (Short, 3 ATRs ) 0.9198999999999999
Upper Bollinger Band 1.1485
Lower Bollinger Band 0.7163
Percent B (%b) 0.05
BandWidth 46.353496
MACD Line -0.0972
MACD Signal Line -0.0838
MACD Histogram -0.0134
Fundamentals Value
Market Cap 26.48 Million
Num Shares 35.8 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -1.72
Price-to-Sales 26.16
Price-to-Book 2.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.82
Resistance 3 (R3) 0.82 0.79 0.81
Resistance 2 (R2) 0.79 0.77 0.79 0.80
Resistance 1 (R1) 0.76 0.75 0.75 0.77 0.80
Pivot Point 0.73 0.73 0.73 0.74 0.73
Support 1 (S1) 0.71 0.71 0.70 0.71 0.68
Support 2 (S2) 0.68 0.70 0.68 0.68
Support 3 (S3) 0.66 0.68 0.67
Support 4 (S4) 0.66